AI Summary
✦ ClarthaValuation Metrics
Trading 47.3% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +2.69). Confidence: 82%.
Live forward EPS implies next-12-month EPS of ₹61.28. Applying the stock's normalized valuation corridor produces a fair range of ₹1,052.79 to ₹1,305.26, with base value near ₹1,165.55 (-15.2% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹61.28
Forward P/E
22.4x
Base Fair Value
₹1,165.55
Fair Range
₹1,052.79 - ₹1,305.26
Upside To Base
-15.2%
Estimate Source
Live forward EPS
Growth Estimate
+31.7%
5Y Average
15.32
Current
28.01
Overvalued
21.30
Undervalued
17.18
5Y Average
10.54
Current
19.26
Overvalued
13.79
Undervalued
7.07
5Y Average
3.56
Current
6.51
Overvalued
4.66
Undervalued
2.39
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -33% vs avg | +22.1% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Undervalued | -25% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Undervalued | -19% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Undervalued | -18% vs avg | +31.7% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 37.5x Undervalued | -20% vs avg | +29.9% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Fair | -7% vs avg | +45.4% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Fair | -7% vs avg | -25.8% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.4x Premium | +129% vs avg | -6.9% |
ALIVUS LIFE SCIENCES LTD trades at a discount (28.0x vs peer avg 46.9x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., GLENMARK PHARMACEUTICALS, ABBOTT INDIA LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹640 CrJun 2026Latest net profit
₹160 CrJun 2026Latest EPS
₹13.04Jun 2026Net margin
33.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses + | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other Income + | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| Profit before tax | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net Profit + | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS in Rs | 11.05 | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 | 13.04 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript